Disclosed is a method of synthesizing a (1R,2R)-nitroalcohol compound of formula (I), as shown in the following reaction scheme, including: subjecting a compound of formula (II) and a compound of formula (III) to a condensation reaction in an organic solvent in the presence of a copper complex generated in situ from a chiral (1S,2R)-amino alcohol ligand and a cupric salt to produce the (1R,2R)-nitroalcohol compound of formula (I), where R.sup.1 and R.sup.2 are defined in the same manner as that in the specification. The method involves mild reaction conditions, excellent diastereoselectivity and high chemical yield, and thus it is suitable for industrial applications.

##STR00001##

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution including at least one of sulfonyl compounds expressed by R(—S(═O).sub.2—Rf).sub.n, where R represents an n-valent hydrocarbon group including one or two or more aliphatic hydrocarbon rings, Rf includes one of a halogen group and a monovalent halogenated hydrocarbon group, n is an integer greater than or equal to 1.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution including at least one of sulfonyl compounds expressed by R(—S(═O).sub.2—Rf).sub.n, where R represents an n-valent hydrocarbon group including one or two or more aliphatic hydrocarbon rings, Rf includes one of a halogen group and a monovalent halogenated hydrocarbon group, n is an integer greater than or equal to 1.

The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.

The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n are defined as above.

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

The present disclosure provides methods for preparing polyunsaturated hydrocarbons, such as E,E-farnesol, farnesyl acetate and squalene, by base catalyzed addition of a dialkylamine to a 3-methylene-1-alkene, such as farnesene. The present disclosure also provides compositions including one more farnesene derivatives prepared using the disclosed methods.

The present disclosure provides methods for preparing polyunsaturated hydrocarbons, such as E,E-farnesol, farnesyl acetate and squalene, by base catalyzed addition of a dialkylamine to a 3-methylene-1-alkene, such as farnesene. The present disclosure also provides compositions including one more farnesene derivatives prepared using the disclosed methods.

The present disclosure provides methods for preparing polyunsaturated hydrocarbons, such as E,E-farnesol, farnesyl acetate and squalene, by base catalyzed addition of a dialkylamine to a 3-methylene-1-alkene, such as farnesene. The present disclosure also provides compositions including one more farnesene derivatives prepared using the disclosed methods.